Evaluation of HZX-960, a novel DCN1–UBC12 interaction inhibitor, as a potential antifibrotic compound for liver fibrosis

State Key Laboratory of Esophageal Cancer Prevention and Treatment; Key Laboratory of Advanced Pharmaceutical Technology, Ministry of Education of China; Co-innovation Center of Henan Province for New Drug R&D and Preclinical Safety; Zhengzhou University School of Pharmaceutical Sciences and Institute of Drug Discovery & Development, Zhengzhou University, 100 Kexue Avenue, Zhengzhou, Henan 450007, China

Department of Pathology, Oslo University Hospital, Faculty of Medicine, University of Oslo, Oslo 0379, Norway

Wenjuan Zhou and Guanjun Dong contributed equally to this work.

留言 (0)

沒有登入
gif